Retail prices of 19 essential medicines fixed
BBN. The National Pharmaceuticals Pricing Authority (NPPA) has fixed the retail prices of 19 essential medicines. These include medicines for the treatment of cancer, hypertension, infection, pain and fever and other medicines.
The National Drug Pricing Authority has issued a notification in this regard. The drug regulator has made this revision in prices under the Drugs (Price Control) Order-2013. According to the notification, companies will be allowed to add GST only on these medicines.
In the notification issued by NPPA quoting Deputy Director Mahavir Saini, the prices of 19 scheduled medicines have been revised. Let us tell you that NPPA fixes the maximum price of essential medicines included in Schedule I under the Drugs Order (DPCO) 2013. Medicines used in the treatment of breast and stomach cancer are also included in this list.
This medicine is manufactured by Hetro and Mankind Pharma, now the new price of this medicine has been fixed at Rs 15,817.49 per vial. Apart from this, the prices of Bisoprolol Umarate and A Lodipine tablet have also been reduced, Garnier Biotech and Zydus Healthcare manufacture this medicine.
The price of each tablet has been fixed at Rs 6.74. Apart from this, the price of hypertension medicine has been reduced to Rs 10, this medicine is manufactured by Pure and Care Healthcare and Cipla company. The maximum price has also been fixed at Rs 40.03 per tablet for Theon Pharma and JB Chemical’s amoxicillin and potassium clavulanate tablets, a type of antibiotic drug, which is used in the treatment of many types of bacterial infections. The notification of NPPA states that if these medicines are sold at a price higher than the fixed retail price, then action will be taken.
